Renier Brentjens

Renier Brentjens conducted the landmark clinical trials at Memorial Sloan Kettering demonstrating that CD19-targeted CAR-T cells could achieve complete remissions in adults with relapsed and refractory acute lymphoblastic leukemia, providing critical clinical validation that helped establish CAR-T cell therapy as a viable cancer treatment modality. His work on optimizing lymphodepletion conditioning regimens for CAR-T cell therapy was essential for achieving the high response rates seen in pivotal trials. He continues to advance clinical cell therapy development for hematologic malignancies and emerging solid tumor applications.